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ABSTRACT
The National Marrow Donor Program (NMDP) has been facilitating hematopoietic cell transplants since 1987.
Volunteer donors listed on the NMDP Registry may be asked to donate either bone marrow (BM) or peripheral
blood stem cells (PBSC); however, since 2003, the majority of donors (72% in 2007) have been asked to donate
PBSC. From the donor’s perspective these stem cell sources carry different recovery and safety profiles. The
majority of BM and PBSC donors experienced symptoms during the course of their donation experience.
Pain is the number 1 symptom for both groups of donors. BM donors most often reported pain at the collection
site (82% back or hip pain) and anesthesia-related pain sites (33% throat pain; 17% post-anesthesia headache),
whereas PBSC donors most often reported bone pain (97%) at various sites during filgrastim administration. Fa-
tigue was the second most reported symptom by both BM and PBSC donors (59% and 70%, respectively). PBSC
donors reported a median time to recovery of 1 week compared to a median time to recovery of 3 weeks for BM
donors. Both BM and PBSC donors experienced transient changes in their WBC, platelet, and hemoglobin
counts during the donation process, with most counts returning to baseline values by 1 month post-donation
and beyond. Serious adverse events are uncommon, but these events occurred more often in BM donors than
PBSC donors (1.34% in BM donors, 0.6% in PBSC donors) and a few BM donors may have long-term compli-
cations. NMDP donors are currently participating in a randomized clinical trial that will formally compare the
clinical and quality-of-life outcomes of BM and PBSC donors and their graft recipients.
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In 1987, when the National Marrow Donor
Program (NMDP) first began matching volunteer
donors with patients in need of a hematopoietic cell
transplant (HCT), the only stem cell source available
through the NMDP was bone marrow (BM). This
changed in 1997 when the NMDP opened a protocol
for the mobilization and collection of peripheral
blood stem cells (PBSC) that was supported by anInvestigational New Drug (IND) application with
the Food and Drug Administration (FDA). This first
protocol was open only to donors who had previously
donated BM, but in 1999, a companion protocol was
opened for first-time donors. By 2003, the number of
PBSC donations exceeded the number of BM dona-
tions. Today, PBSC donations comprise over 70%
of all adult donor donations. From the donor’s per-
spective these two stem cell sources carry different29
30 J. P. Miller et al.recovery and safety profiles. In 2004, the NMDP be-
gan enrolling donors in the PBSC versus Marrow
Randomized Trial (0201) sponsored by the NMDP,
and the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN). This trial will formally com-
pare the clinical and quality-of-life outcomes of BM
and PBSC donors.
We review the course of donor recovery from BM
and PBSC donations and the serious adverse events
and long-term complications associated with these
two types of donation.
METHODS
Study Population
This report summarizes the donation and recovery
experiences of first-time BM and PBSC donors whose
donations were from November 2001 through March
2006. Also summarized are the acute and long-term
complications of a cohort of BM donors whose collec-
tions were performed from December 1987 through
December 1999 and the entire cohort of PBSC donors
whose collections were performed fromFebruary 1997
through December 31, 2007.
Overview of BM and PBSC Donation
All HCT donors donating BM or PBSC receive
a medical history and physical examination prior to
their donation to exclude the presence of physical con-
ditions that might increase their risk of donation or the
risk to the recipient.
BM Donors
Depending on the volume of marrow they will do-
nate, donors have 1 to 3 autologous units of blood col-
lected prior to their marrow collection tominimize the
likelihood of needing allogeneic transfusion. The do-
nor’s marrow is collected from the posterior iliac crests
under either general or regional anesthesia. NMDP
standards allow for a maximum of 20 mL marrow/kg
donor weight to be collected. In the early years of the
program, virtually all BM donors were hospitalized
for 1 or 2 nights, but today, most donors are
admitted to a same-day surgical unit on the morning
of their donation and are discharged by late afternoon.
PBSC Donors
PBSCdonors receive filgrastim at a targeted dose of
10–12 mg/kg of body weight subcutaneously for 5 con-
secutive days.Onday5 alone, or on days 5 and6, the do-
nor’s PBSC are collected by leukapheresis. The volume
ofwhole blood processed ranges from12 to 24 liters per
collection, depending on recipient weight and/or de-
gree of CD34 mobilization in the donor. Although the
use of central venous catheters is discouraged, central
venous catheters were inserted in about 1 in 5 womenand 1 in 20 men. Issues surrounding central venous
catheters are discussed in this issue of the Journal.
Data Collection—Pre- and Post-donation
Assessment for Marrow and PBSC Donors
Abaseline symptom assessment is completed onBM
and PBSC donors at the time of their physical examina-
tion and on the day of donation. Symptom assessments
are also completed on PBSC donors on each day of fil-
grastim, just prior to the injection. Both BM and PBSC
donors are contacted by the donor center post-donation
at 2 days, 1 week, 1month, 6months, and annually to as-
sess the presense of any new or residual symptoms. Do-
nor symptoms are assessed using selected components of
the NCI Common Terminology Criteria for Adverse
Events (CTCAE 3.0). In addition, the annual follow-
up includes a complete blood count (CBC) and white
cell differential. Donors participating in BMT CTN
0201, the PBSC versus Marrow Randomized Trial, are
also required to have CBC and differential performed
at 1 month and 6 months post-donation.
RESULTS
Donor Symptoms Experienced During BM or
PBSC Donation
Most BM donors and PBSC donors experienced
symptoms during the course of their donation. Symp-
toms experienced by BM donors are almost always re-
lated to the collection of the marrow, whereas
symptoms experienced by PBSC donors aremost often
associated with the administration of filgrastim.
Symptoms Experienced by BM Donors
Pain was the most common symptom experienced
by first-time stem cell donors. Figure 1A illustrates the
most common pain sites and percentage of BM donors
experiencing pain at various sites over time.
Pain directly related to the collection was most of-
ten reported by donors. At day 2 post-donation, 82%
of donors reported either back pain or hip pain or
both. Pain sites related to the anesthesia were also
common, with 33% of donors experiencing throat
pain and 17% experiencing headache on day 2 post-
donation. Of those donors who experienced pain, the
majority reported mild (grade 1) pain regardless of
the pain site. By 1 month post-donation the pain had
resolved for over 80% of donors. By 1 year the propor-
tion of donors who reported any pain went down to
\10%, which was similar to the baseline percentage.
Figure 1B illustrates the 6most frequently reported
symptoms other than pain over time. The most
frequently reported symptom was fatigue, with 59%
of donors reporting fatigue on day 2 post-collection;
(46% mild [grade 1], 12% moderate [grade 2], 1%
severe [grade 3] and\1% disabling [grade 4]). By 1
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Figure 1. (A) Percentage of BMdonors reporting pain at selected sites over time. Reports of pain and pain severity were collected at the indicated
time points post-donation. Throat pain is largely restricted to donors receiving general anesthesia, whereas headache is more common in donors
receiving regional anesthesia, for example, epidural. (B) Six most frequently reported body symptoms experienced by BM donors at the indicated
time points post-donation.month post-donation only 5% of donors were still
experiencing some fatigue.
Symptoms Experienced by PBSC Donors
Among the first-time stem cell donors going
through mobilization and PBSC collection between
November 2001 and March 2006, the most common
symptom experienced was bone pain at various sites
with 89% of donors reporting bone pain on day 5,
the first day of collection (51% had mild pain, 35%
had moderate pain, 3% had severe pain, and \1%reported disabling pain). By 1 week post-donation
90% of donors reported that the bone pain had re-
solved (Figure 2A).
At some point over the course of mobilization and
collection (day 1 to day 5 or 6), 97% of donors experi-
enced some degree of bone pain. The maximum sever-
ity of bone pain reported during this time was mild in
41%, moderate in 50%, severe in 6%, and disabling in
\1% of donors.
Figure 2B illustrates the 6 most frequently re-
ported symptoms other than bone pain by PBSC
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Figure 2. (A) Percentage of PBSC donors reporting bone pain over time. Reports of bone pain and severity of pain were collected at the indicated
time points during mobilization, collection, and post-donation. Day 1 is the first day of filgrastim administration; day 5 is the first day of apher-
esis. Bone pain represents pain in at least one of the following sites: general bone pain, back, head, limb, joint, hip, and neck. The severity of bone
pain is defined as the maximum grade among these pain sites. (B) Six most frequently reported body symptoms experienced by PBSC donors
during mobilization and collection, and at the indicated time points post-donation. The percentages for day 1 to day 6 represent the frequencies
of the highest grade of symptoms during mobilization and collection.donors. Fatigue was the most commonly reported
symptom, with 70% of donors experiencing fatigue
at some point during mobilization and collection, fol-
lowed by myalgia (49%), insomnia (48%), nausea
(26%), and anorexia (22%). Most symptoms were
mild (grade 1).
Hematology
Donors undergoing either BM or PBSC donation
experienced changes in their WBC, platelet, and he-moglobin values during the donation process. BM
donors experienced changes in blood cell counts im-
mediately following the donation mostly from loss of
marrow and blood, whereas PBSC donors experienced
changes in these values during both filgrastim admin-
istration and immediately following donation.
BM Donors
Almost all donors donated autologous units prior
to the marrow collection, and the majority (76%)
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Figure 3. Box and whiskers plot of BM donor hemoglobin levels showing the maximum, upper quartile, median, lower quartile, and minimum
values at baseline, the day of collection, and the indicated time points post-donation.received at least 1 autologous unit after the marrow
donation.
Immediately post-donation the median WBC of
evaluated donors was 9.7  109/L (interquartile range
7.6 to 12.7), compared to a baselinemedian value of 6.3
 109/L (interquartile range 5.3 to 7.4). This post-
donation increase in WBC values is most likely be-
cause of the stress of the donation and anesthesia. By
1 month post-donation the median WBC of evaluated
donors had returned to baseline values and at 3 years
post-donation the median WBC was unchanged
from baseline.
A slight decrease in median platelet counts was ob-
served from baseline (251 109/L, interquartile range
217 to 292) to immediately post-donation (214  109/
L, interquartile range 179 to 252). By 1 month post-
donation median platelet counts had returned to base-
line levels and remained at baseline levels at 3 years
post-donation.
When compared with baseline hemoglobin values
(males: median 15.4 g/dL, interquartile range 14.8 to
16.1; females: median 13.6 g/dL, interquartile range
12.8 to 14.1), a decrease in hemoglobin values was ob-
served in both female and male donors immediately
post-donation (males: median 12.4 g/dL, interquartile
range 11.5 to 13.4; females: median 10.3 g/dL, inter-
quartile range 9.4 to 11.3). A mild decrease in hemo-
globin values persisted at 1 month post-donation for
both male (median 14.4 g/dL, interquartile range
14.0 to 15.0) and female (median 12.1 g/dL, interquar-
tile range 11.5 to 13.1) donors but returned to baseline
levels by 1 year post-donation and remained at baseline
levels at 3 years post-donation (Figure 3).PBSC Donors
Not surprisingly, by day 5 of filgrastim injections,
PBSC donors experienced steep increases in their
WBC values to a median of 38.5 109/L (interquartile
range 30.7 to 47.1). At 1 month post-donation, WBC
values were slightly decreased from baseline (baseline:
median 6.3  109/L, interquartile range 5.3 to 7.6; 1
month: median 5.5  109/L, interquartile range 4.6
to 6.6) but by 1 year post-donation, WBC values
were indistinguishable from baseline levels and re-
mained there at 3 years post-donation (Figure 4A).
Platelets declined slightly from baseline values
over the 5 day course of filgrastim but declined dra-
matically immediately post-apheresis (baseline: me-
dian 253  109/L; interquartile range 219 to 291;
day 5 post-apheresis: median 136  109/L; interquar-
tile range 107 to 168). By 1 month post-donation, the
majority of donors had platelet values within the nor-
mal range (median 242  109/L; interquartile range
209 to 282). At 1 year post-donation, platelet counts
returned to baseline levels and remained there at 3
years post-donation (Figure 4B). Significant thrombo-
cytopenia is rare post-donation; donors with this find-
ing are discussed in more detail below.
For both male and female donors, hemoglobin
levels remained at baseline levels throughout the 5
day mobilization period but decreased immediately
post-apheresis to a median of 13.8 109/L (interquar-
tile range 13.2 to 14.4) for males and 11.7 109/L (in-
terquartile range 11.2 to 12.4) for females on the first
day of donation. For both male and female donors, he-
moglobin values had returned to baseline levels by
34 J. P. Miller et al.0
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Figure 4. (A) Box and whiskers plot of PBSC donorWBC counts showing the maximum, upper quartile, median, lower quartile, and minimum
values at the indicated time points during mobilization, collection, and post-donation. (B) Box and whiskers plot of PBSC donor platelet counts
showing the maximum, upper quartile, median, lower quartile, and minimum values at the indicated time points during mobilization, collection,
and post-donation. (C) Box and whiskers plot of PBSC donor hemoglobin levels showing the maximum, upper quartile, median, lower quartile,
and minimum values at the indicated time points during mobilization, collection, and post-donation. (Day 1 is the first day of filgrastim admin-
istration; day 5 is the first day of apheresis; pre and post refer to the apheresis procedure.)1 year post-donation and remained there at 3 years
post-donation (Figure 4C).
Time to Recovery from BM and PBSC Donations
Time to recovery is a donor-reported measure;
each marrow and PBSC donor is contacted weekly
post-donation until the donor confirms complete
recovery from their procedure (Figure 5).
PBSC donors recovered from their donation in less
time than BM donors, with a median time to recovery
of 1 week for PBSC donors compared to 3 weeks for
BM donors. By 4 weeks post-donation, 92% of PBSC
donors reported full recovery compared to 69% of
BMdonors. About 5%of donors follow their initial do-
nation with a second donation of marrow or PBSC
weeks to months later. Median time to recovery from
these second donations did not differ from median
time to recovery from a first donation, with median re-covery times of 1 week for PBSC and 3 weeks for BM
donors. By 4 weeks post-donation, 94% of PBSC
donors and 68% of BM donors reported full recovery.
Acute and Long-TermComplications from BM and
PBSC Donations
As detailed above, almost all BM and PBSC donors
experienced mild to moderate symptoms during the
course of their donation, but a few experienced serious
acute and long-term complications. In the case of
NMDP BM and PBSC donors, hospitalization is the
most common reason for an adverse event to be rated
as serious.
BM Donors
In a retrospective review of data reported on stan-
dardized follow-up forms from 9245 NMDP marrow
collections performed between December 1987 and
Donor Outcomes 35December 1999, 345 (3.7%) donors with a potentially
serious medical complication were identified. These
complications included excessive pain, adverse acute
anesthesia reaction, delayed return to normal activi-
ties, and need for additional medical intervention. A
panel of 5 physicians reviewed all 345 cases; 125
(1.35% of the 9245 total) were determined to be seri-
ous post-donation complications. Of these 125 serious
cases, 116 were classified as directly related to the col-
lection with the proximal cause relative to the collec-
tion being: (1) mechanical injury to tissue, bone or
nerve (n5 69, 55%; 0.7 of the 9245 total); (2) anesthe-
sia (n5 45, 36%; 0.5% of the total); (3) infection (n5
1, 1%; 0.01% of the total); and (4) grand mal seizure
(n 5 1, 1%; 0.01% of the total).
Of the 116 donors with serious complications, 67
(0.7% of the 9245 total) experienced prolonged recov-
ery times (median 10 months, range 1 to 96 months)
related to mechanical injury to tissue from needle
aspirations, and required interventions ranging from
limited physician involvement and/or physical therapy
to surgical intervention and ongoing disability (1 to
.10 years). Of the remaining 49 donors (0.5% of the
9245 total) with severe reactions, most were because
of severe acute reactions related to the anesthesia.
These anesthesia-related acute reactions included
complicated post-spinal headaches, cardiac arrhyth-
mias, and pulmonary edema. Acute reactions were
short-lived, and all resolved within hours to days after
the collection.
Multivariate analyses indicated that regional anes-
thesia, longer duration of collection, female sex, and
older donor age were significant risks for serious com-
plications.
Overall, the incidence of serious complications
from marrow donation is low (1.35%), with mechani-
cal injury the most frequent cause of prolonged post-
donation recovery and anesthesia-related events the
most frequent cause of severe acute reactions.
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Figure 5. Kaplan-Meier plots of time to recovery from stem cell
donation (first donations performed from November 2001 through
March 2006).PBSC Donors
Serious adverse events in PBSC donors occurred at
about half the rate (0.6%) of BM donors and the ma-
jority are acute, short-lived events.
On data collected from 7850 PBSC donors from
February 1, 1997 to December 31, 2007, a total of 44
(0.6%) serious adverse events were reported to the
FDA. After medical monitor review, 39 of the 44 seri-
ous adverse events were determined to be related, or at
least possibly related, to either filgrastim administra-
tion or PBSC donation.
Of the 39 events related to filgrastim and PBSCdo-
nation, themajority (37 [95%]) were rated as serious by
virtue of the donor being hospitalized. Twenty-five
donors were hospitalized with severe symptoms such
as headache, nausea and vomiting, chest pain, and tet-
any because of low calcium; 4 donors with central line
complications; 4 with low platelet counts; 2 with
pneumonia, 1 with asthma, and 1 with a deep vein
thrombosis.
Two donors experienced serious events but were
not hospitalized. One had a history of benign micro-
scopic hematuria that progressed to gross hematuria
by day 3 of filgrastim administration. By 6 weeks post-
donation thegrosshematuria had resolved and returned
to the baseline level of benign microscopic hematuria.
Another donor, a 40-year-old Caucasian female,
developed typical immune thrombocytopenic purpura
about 4 weeks post-donation. She was managed with
corticosteroid therapy and eventually achieved a lasting
complete remission. Three other donors had severe
thrombocytopenia following apheresis. In each of
these cases, the donors evidenced low or low-normal
baseline platelet counts, which fell precipitously dur-
ing administration of filgrastim. In each case the plate-
let levels returned to baseline values after PBSC
donation. These cases may represent individuals with
shortened platelet survival at baseline whose condition
is aggravated by the PBSC donation process.
Five of the 39 serious adverse events were com-
plications from central line placement. These events
included 2 cases of excessive bleeding controlled with
pressure, 1 case of a hematoma after the central line
was removed, 1 severe vasovagal reaction, and 1 case
of severe hypotension that occurred during apheresis
and was apparently cardiac in origin.
SUMMARY
The recovery and safety profiles for BM and PBSC
donors have both similarities and differences. BM
donors most often experienced pain after the collec-
tion at the collection site or sites related to the anesthe-
sia, whereas PBSC donors most often experienced
bone pain during filgrastim administration. Both BM
and PBSC donors experienced transient changes in
their WBC, platelet, and hemoglobin counts during
36 J. P. Miller et al.the donation process. PBSC donors reported faster re-
covery from their donation than BM donors, with
PBSC donors reporting a median time to recovery of
1 week compared to 3 weeks for BM donors. Although
both BM and PBSC donors experienced serious ad-
verse events, these occurred more frequently in BM
donors (1.34% versus 0.6% for PBSC donors) and
a few led to long-term complications not reported by
PBSC donors.
The ongoingBMTCTNrandomized trial will for-
mally compare the clinical and quality-of-life outcomes
of BM and PBSC donors and their recipients. This trial
will help to further demonstrate any differences in the
recovery and safety profiles of these 2 types of dona-tions and may help bring further clarity on how best
to balance recipient and donor considerations when se-
lecting the stem cell source for transplantation.
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